Copies of letters sent to healthcare professionals in February 2013, to inform of new safety information and advice:

Date sent Medicine Safety information
20 February 2013 Denosumab 60mg (Prolia▼)PDF file (opens in new window) (108Kb) Rare risk of atypical femoral fracture noted with Prolia use in a clinical trial.
25 February 2013 Botulinium Toxin Type B (Neurobloc)PDF file (opens in new window) (136Kb) Rare cases of distant toxin spread have been reported with Neurobloc; most of these cases occurred with off-label use.
28 February 2013 Synarel nasal sprayPDF file (opens in new window) (131Kb) Restricted supply of Synarel 2 mg/mL (8 mL bottles) – product allocation is restricted to mid-cycle patients only.
28 February 2013 Gadoversetamide injection (Optimark)PDF file (opens in new window) (208Kb) Peel-off tracking labels have been introduced for all gadolinium-containing contrast agents, in order to trace their use.









Posted on the UK MHRA on 1 March 2013